

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6071010

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

CONVEYING PARTY DATA

Name	Execution Date
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED	04/21/2020

RECEIVING PARTY DATA

Name:	DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Street Address:	60 WALL STREET
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10005

PROPERTY NUMBERS Total: 13

Property Type	Number
Application Number:	16724786
Application Number:	16704530
Application Number:	16748319
Application Number:	16677435
Application Number:	16696142
Application Number:	16779912
Application Number:	16785983
Application Number:	16785978
Application Number:	62948513
Application Number:	16778696
Application Number:	16732861
Application Number:	62965330
Application Number:	16779796

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2136207848

Email: iprecordations@whitecase.com

Correspondent Name: JUSTINE LU/WHITE & CASE LLP

PATENT

Address Line 1: 555 SOUTH FLOWER STREET, 2700
Address Line 4: LOS ANGELES, CALIFORNIA 90071

ATTORNEY DOCKET NUMBER: 1111779-2659-S216

NAME OF SUBMITTER: JUSTINE LU

SIGNATURE: /Justine Lu/

DATE SIGNED: 04/21/2020

Total Attachments: 7

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page1.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page2.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page3.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page4.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page5.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page6.tif

source=MNK - April 2020 IP Supplement - CAGR - Notice of Grant of Security Interest in Patents
[Executed]#page7.tif

Notice of Grant of Security Interest in Intellectual Property

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of April 21, 2020 (this “**Agreement**”), made by Mallinckrodt Hospital Products IP Limited, a private limited company incorporated in Ireland with registered number 568351, Ocera Therapeutics, Inc., a Delaware corporation, and ST Shared Services LLC, a Delaware limited liability company (each, a “**Pledgor**” and collectively, the “**Pledgors**”), in favor of DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent (as defined below).

Reference is made to the U.S. Collateral Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the “**U.S. Collateral Agreement**”), among Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (*R.C.S. Luxembourg*) under number B 172.865 (the “**Lux Borrower**”), MALLINCKRODT CB LLC (the “**Co-Borrower**”, and together with the Lux Borrower, the “**Borrowers**”), Mallinckrodt Holdings GmbH (as successor by merger to Mallinckrodt Finance GmbH) (the “**Swiss Finco**”), each other Subsidiary Loan Party listed on the signature pages thereof and each other Subsidiary Loan Party that becomes a party thereto after the date thereof and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the “**Collateral Agent**”) for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. **Grant of Security Interest.** As security for the payment and performance, as applicable, in full of its Secured Obligations, each Pledgor pursuant to the U.S. Collateral Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of each such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by each such Pledgor or in which each such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “**IP Collateral**”):

all Patents of the United States of America of each Pledgor, including those listed on Schedule I;

SECTION 3. **U.S. Collateral Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the U.S. Collateral Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by

reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the U.S. Collateral Agreement, the terms of the U.S. Collateral Agreement shall govern.

SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. *Governing Law*. **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MALLINCKRODT HOSPITAL PRODUCTS IP
LIMITED

By: 

Name: Alasdair Fenlon
Title: Director

OCERA THERAPEUTICS, INC.

By: _____

Name: John Einwalter
Title: Vice President & Treasurer

ST SHARED SERVICES LLC

By: _____

Name: John Einwalter
Title: Vice President & Treasurer


[Signature Page to Notice of Grant of Security Interest in Patents]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.


MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED

By: _____
Name: Alasdair Fenlon
Title: Director


OCERA THERAPEUTICS, INC.


By:  _____
Name: John Einwalter
Title: Vice President & Treasurer

ST SHARED SERVICES LLC

By:  _____
Name: John Einwalter
Title: Vice President & Treasurer

DEUTSCHE BANK AG NEW YORK BRANCH,
as Collateral Agent,

By: 
Name: Philip Tancorra
Title: Vice President
philip.tancorra@db.com
212-250-6576

By: 
Name: Alicia Schug
Title: Vice President
alicia.schug@db.com
212.250.4796

Schedule I
to Notice of Grant of Security Interest in Patents

U.S. Patent Registrations

N/A

U.S. Patent Applications

Patent	Application No.	Application Date	Owner
APPARATUS AND METHOD FOR DETECTING LIQUID LEVEL IN A CLEAR OR PARTIALLY CLEAR CONTAINER	16/724786	12/23/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
ENHANCED PERFORMANCE VERIFICATION PORT FOR THERAPEUTIC GAS DELIVERY	16/704530	12/5/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS	16/748319	1/21/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
CLINICAL DECISION SUPPORT SYSTEM AND METHODS	16/677435	11/7/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEMS AND METHODS FOR INDICATING LIFETIME OF AN NO ₂ -TO-NO REACTOR CARTRIDGE USED TO DELIVER NO FOR INHALATION THERAPY TO A PATIENT	16/696142	11/26/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEM AND METHOD OF ADMINISTERING A PHARMACEUTICAL GAS TO A PATIENT	16/779912	2/3/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
METHODS OF ADMINISTERING HIGH CONCENTRATIONS OF NITRIC OXIDE	16/785983	2/10/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
CANNULA FOR MINIMIZING DILUTION OF DOSING DURING NITRIC OXIDE DELIVERY	16/785978	2/10/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
METHODS FOR TREATING PROGRESSIVE HYPERBILIRUBINEMIA	62/948513	12/16/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF	16/778696	1/31/2020	OCERA THERAPEUTICS, INC.

TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES	16/732861	1/2/2020	OCERA THERAPEUTICS, INC.
DOSAGES AND USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA	62/965330	1/24/2020	OCERA THERAPEUTICS, INC.
(+)-MORPHINAN COMPOUNDS AS SMALL MOLECULE ANTAGONISTS OF TOLL-LIKE RECEPTOR 9	16/779796	2/3/2020	ST SHARED SERVICES LLC